



**TTK Healthcare**  
**LIMITED**

TTKH:SEC:SL:134:25

May 23, 2025

**BSE Limited**  
**Phiroze Jeejeebhoy Towers**  
**Dalal Street**  
**Mumbai 400 001**

**Scrip Code: 507747**

**National Stock Exchange of India Limited**  
**Exchange Plaza**  
**Bandra Kurla Complex, Bandra East**  
**Mumbai 400 051**

**Scrip Code: TTKHLTCARE**

Dear Sirs,

**Re : Outcome of the Board Meeting – Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015**

---

Pursuant to the provisions of Regulations 30 & 33 of the SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, *inter alia* considered and approved / recommended the following:

- (i) The Audited Financial Results along with the Statutory Auditors' Report with unmodified opinion and Declaration by the Executive Chairman that the Audit Report is with unmodified opinion, for the Fourth Quarter and Year Ended March 31, 2025, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on May 22, 2025, are attached herewith as **Annexure–A**.
- (ii) Dividend of Rs.10/- per Equity Share of Rs.10/- each (100%), for the financial year ended March 31, 2025 which shall be paid within 30 days from the date of AGM, subject to the approval of the Shareholders.
- (iii) The 67<sup>th</sup> Annual General Meeting of the Company has been scheduled to be held on **Friday, July 25, 2025**, through Video Conferencing / Other Audio Visual Means (VC / OAVM).
- (iv) Appointment of M/s A K Jain & Associates, Practising Company Secretaries, represented by its Partners - Mr Balu Sridhar / Mr Pankaj Mehta, Partners, as the Scrutinizer for conducting the voting process at the 67<sup>th</sup> Annual General Meeting of the Company.
- (v) Appointment of M/s Geeyes & Co. as the Cost Auditor of the Company for the financial year 2025-26, as per the provisions of Section 148 of the Companies Act, 2013 and the Rules made thereunder and fixed their remuneration. (The information required pursuant to the provisions of Schedule III of the SEBI (LODR) Regulations, 2015 is enclosed as **Annexure – B**).
- (vi) A brief highlight of the Audited Financial Statements for the year ended March 31, 2025 is enclosed as **Annexure - C**.

..... 2



---

**TTK Healthcare**  
**LIMITED**

---

**2**

We request you to kindly take the above information / documents on record.

The meeting of the Board of Directors was held physically also with the facility of **Video Conferencing** which commenced at 12 noon and concluded at 01.30 p.m.

Thanking you

Yours faithfully  
**For TTK Healthcare Limited**

**(GOWRY A JAISHANKAR)**  
*DGM - Legal & Company Secretary*

**Encl. : a/a**



**Notes:**

- (1) The above financial results for the Fourth Quarter and Year ended March 31, 2025 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on May 22, 2025 and approved by the Board of Directors of the Company at its meeting held on May 23, 2025 at the Registered Office of the Company, also with the provision of Video Conferencing facility. The Statutory Auditors have audited the above results and have issued an unmodified opinion.
- (2) During the First Quarter of this financial year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
- (3) During the Fourth Quarter of this financial year, the Company has written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- (4) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond April 01, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (5) The Board has recommended a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the financial year ended March 31, 2025.
- (6) The figures for the Quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to limited review.
- (7) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (8) This statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)), National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- (9) **Statement of Assets and Liabilities as at March 31, 2025:**

Sl. No.	Particulars	(Rs. in lakhs)	
		As on 31/03/2025	As on 31/03/2024
		Audited	Audited
<b>(A) ASSETS:</b>			
<b>I Non-Current Assets:</b>			
(a)	Property, Plant and Equipment	6,776.15	6,142.30
(b)	Right of Use Asset	1,313.74	1,337.70
(c)	Capital Work-in-Progress	8.28	79.02
(d)	Other Intangible Assets	-	0.58
(e)	Financial Assets		
(i)	Investments	1,121.82	1,255.80
(ii)	Others Financial Assets	6,990.79	2,581.35
(f)	Non-current Tax Assets (Net)	895.16	800.94
(g)	Deferred Tax Assets (Net)	595.08	544.35
(h)	Other Non-current Assets	28.47	158.05
	<b>Total Non-Current Assets</b>	<b>17,729.49</b>	<b>12,900.09</b>
<b>II Current Assets:</b>			
(a)	Inventories	10,858.86	9,698.98
(b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade Receivables	9,052.85	8,644.02
(iii)	Cash and Cash Equivalents	900.64	1,095.93
(iv)	Bank balances other than (iii) above	77,748.36	76,398.10
(v)	Other Financial Assets	10,226.59	9,977.77
(c)	Current Tax Assets (Net)	117.27	85.50
(d)	Other Current Assets	1,484.61	1,829.59
	<b>Total Current Assets</b>	<b>1,10,389.18</b>	<b>1,07,729.89</b>
	<b>TOTAL ASSETS</b>	<b>1,28,118.67</b>	<b>1,20,629.98</b>



Sl. No.	Particulars	(Rs. in lakhs)	
		As on	As on
		31/03/2025	31/03/2024
		Audited	Audited
<b>(B)</b>	<b>EQUITY AND LIABILITIES:</b>		
<b>(1)</b>	<b>Equity</b>		
	(a) Equity Share Capital	1,413.03	1,413.03
	(b) Other Equity	1,05,091.79	98,678.86
	<b>Equity attributable to owners of the Company</b>	<b>1,06,504.82</b>	<b>1,00,091.89</b>
	<b>Total Equity</b>	<b>1,06,504.82</b>	<b>1,00,091.89</b>
<b>(2)</b>	<b>Liabilities</b>		
	<b>Non-current Liabilities:</b>		
	(a) Financial Liabilities:		
	(i) Lease Liabilities	177.28	79.87
	(b) Provisions	344.26	306.07
	<b>Total Non-current Liabilities</b>	<b>521.54</b>	<b>385.94</b>
	<b>Current Liabilities:</b>		
	(a) Financial Liabilities		
	(i) Borrowings	2,193.51	2,147.30
	(ia) Lease Liabilities	51.16	53.89
	(ii) Trade Payables:		
	(A) Total outstanding dues to Micro Enterprises and Small Enterprises	2,342.17	2,660.18
	(B) Total outstanding dues to creditors other than Micro Enterprises and Small Enterprises	8,341.84	7,566.02
	(iii) Other Financial Liabilities	5,120.16	4,876.99
	(b) Other Current Liabilities	388.31	411.37
	(c) Provisions	2,084.65	1,865.89
	(d) Current Tax Liabilities (Net)	570.51	570.51
	<b>Total Current Liabilities</b>	<b>21,092.31</b>	<b>20,152.15</b>
	<b>TOTAL LIABILITIES</b>	<b>21,613.85</b>	<b>20,538.09</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,28,118.67</b>	<b>1,20,629.98</b>

(10) Statement of Cash Flow for the year ended 31st March, 2025:

Particulars	(Rs. in lakhs)	
	For the year ended	For the year ended
	(31/03/2025)	(31/03/2024)
	Audited	Audited
<b>Cash Flow from Operating activities:</b>		
<b>Profit Before tax from operations</b>	<b>10,833.18</b>	<b>8,412.03</b>
<b>Adjustments for:</b>		
Remeasurements of defined benefit plans	(268.96)	(114.90)
Depreciation and amortisation Expenses	833.37	1,305.87
Provision for Doubtful Debts	28.04	(0.65)
Bad debts written off (Net of Recovery)	32.89	56.73
Creditors written back	(45.38)	(5.74)
Interest paid	332.42	275.55
Interest received	(6,940.67)	(6,210.90)
(Profit) / Loss on Sale of Assets	(15.51)	(9.37)
(Profit) / Loss on Sale of Leased Assets	(2,092.63)	-
Loss on Impairment	0.06	11.97
Loss of Obsolescence	0.06	-
Dividend income	(10.85)	(10.81)
Un Realised Forex (Gain) / Loss	9.88	(4.62)
Deferred Revenue Income	-	(170.36)
<b>Operating Profit before working Capital Changes:</b>	<b>2,695.90</b>	<b>3,534.80</b>
<b>Adjustments for Working Capital changes:</b>		
Inventories	(1,159.88)	(1,247.52)
Trade receivables	(478.01)	514.49
Other Receivables	317.80	(20.56)
Trade payables	477.48	(854.91)
Other liabilities	530.12	75.06
<b>Cash generated from operations:</b>	<b>2,383.41</b>	<b>2,001.36</b>
<b>Less: Direct Taxes Paid</b>	<b>2,780.98</b>	<b>2,495.69</b>
<b>Add: Direct Taxes Received</b>	<b>-</b>	<b>-</b>
<b>Net Cash generated from (used in) Operating Activities</b>	<b>(397.57)</b>	<b>(494.33)</b>



Particulars	(Rs. in lakhs)	
	For the year ended	For the year ended
	(31/03/2025)	(31/03/2024)
	Audited	Audited
<b>Cash Flow from Investing Activities:</b>		
Purchase of Property, Plant and Equipment, Other Intangible Assets and Capital advances	(1,283.98)	(1,038.34)
Proceeds from the sale of Property, Plant and Equipment and Other Intangible Assets (other than Right of Use Asset)	122.92	10.35
Proceeds from the sale of Right of Use Asset	2,206.65	2.20
Investments in Bank deposits (Net)	(5,567.21)	(1,869.24)
Interest received	6,521.11	5,733.57
Dividend Received	10.85	10.81
<b>Net Cash generated from (used in) investing Activities</b>	<b>2,010.34</b>	<b>2,849.35</b>
<b>Cash Flow from Financing Activities:</b>		
Borrowings (Net of repayment)	46.21	(405.53)
Principal repayment of Lease Liabilities	(62.13)	(58.44)
Interest Paid on other than Lease Activity	(365.22)	(291.70)
Interest Paid on Lease Activity	(13.89)	(22.42)
Dividend Paid	(1,413.03)	(1,413.03)
<b>Net Cash generated from (used in) Financing Activities</b>	<b>(1,808.06)</b>	<b>(2,191.12)</b>
Net Increase / (Decrease) in Cash and Cash Equivalents	(195.29)	163.90
Cash and Cash Equivalents as at the beginning of the year	1,095.93	932.03
<b>Total</b>	<b>900.64</b>	<b>1,095.93</b>
<b>Cash and Cash Equivalents as at the end of the year (as per Balance Sheet)</b>	<b>900.64</b>	<b>1,095.93</b>

For TTK HEALTHCARE LIMITED

Place : Chennai  
Date : May 23, 2025

T T RAGHUNATHAN  
Executive Chairman



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
 CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

**SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES  
 FOR THE FOURTH QUARTER AND YEAR ENDED MARCH 31, 2025**

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		(31/03/2025)	(31/12/2024)	(31/03/2024)	(31/03/2025)	(31/03/2024)
		Audited	Unaudited	Audited	Audited	Audited
1.	<b>Segment Revenue: (Sales and Other Operating Income)</b>					
	(a) Animal Welfare	3,060.10	3,281.91	2,899.39	12,637.05	11,551.45
	(b) Consumer Products	5,290.85	5,936.72	5,052.59	24,492.52	23,237.33
	(c) Medical Devices	2,259.66	2,144.79	1,988.23	9,014.53	8,049.04
	(d) Protective Devices	4,759.60	5,936.82	4,832.52	20,663.87	19,986.46
	(e) Foods	3,653.95	3,167.66	3,321.89	13,305.98	12,414.33
	(f) Others	11.80	6.58	11.01	35.39	40.77
	<b>Total</b>	<b>19,035.96</b>	<b>20,474.48</b>	<b>18,105.63</b>	<b>80,149.34</b>	<b>75,279.38</b>
	Less : Inter Segment Revenue	-	-	-	-	-
	<b>Net Sales / Income from Operations</b>	<b>19,035.96</b>	<b>20,474.48</b>	<b>18,105.63</b>	<b>80,149.34</b>	<b>75,279.38</b>
2.	<b>Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]</b>					
	(a) Animal Welfare	320.37	297.54	431.56	1,098.52	1,050.95
	(b) Consumer Products	285.43	645.08	381.97	2,345.32	1,621.59
	(c) Medical Devices	642.65	525.39	405.66	2,215.05	1,692.89
	(d) Protective Devices	631.76	(31.10)	560.02	252.62	1,595.52
	(e) Foods	132.96	143.12	(81.02)	449.89	(310.68)
	(f) Others	(9.90)	8.06	9.48	14.70	(64.74)
	<b>Total</b>	<b>2,003.27</b>	<b>1,588.09</b>	<b>1,707.67</b>	<b>6,376.10</b>	<b>5,585.53</b>
	Less : Finance Cost	90.47	82.33	92.96	332.42	275.55
	Less : Unallocable Expenses (Net of Unallocable Income) (Refer Note 3 below)	(262.80)	(753.59)	(807.92)	(4,789.50)	(3,102.05)
	<b>Total Profit (+) / Loss (-) before tax</b>	<b>2,175.60</b>	<b>2,259.35</b>	<b>2,422.63</b>	<b>10,833.18</b>	<b>8,412.03</b>
		<b>As on 31/03/2025</b>	<b>As on 31/12/2024</b>	<b>As on 31/03/2024</b>	<b>As on 31/03/2025</b>	<b>As on 31/03/2024</b>
3.	<b>Segment Assets:</b>					
	(a) Animal Welfare	3,859.37	4,004.22	3,999.99	3,859.37	3,999.99
	(b) Consumer Products	4,521.96	4,002.19	4,702.91	4,521.96	4,702.91
	(c) Medical Devices	7,135.97	6,857.97	6,409.49	7,135.97	6,409.49
	(d) Protective Devices	13,715.76	13,468.01	12,293.07	13,715.76	12,293.07
	(e) Foods	6,931.64	6,724.78	6,727.70	6,931.64	6,727.70
	(f) Others	289.73	296.75	281.56	289.73	281.56
	<b>Total</b>	<b>36,454.43</b>	<b>35,353.92</b>	<b>34,414.72</b>	<b>36,454.43</b>	<b>34,414.72</b>
	Unallocated	91,664.24	91,867.45	86,215.26	91,664.24	86,215.26
	<b>Total Assets</b>	<b>1,28,118.67</b>	<b>1,27,221.37</b>	<b>1,20,629.98</b>	<b>1,28,118.67</b>	<b>1,20,629.98</b>



		As on 31/03/2025	As on 31/12/2024	As on 31/03/2024	As on 31/03/2025	As on 31/03/2024
<b>4.</b>	<b>Segment Liabilities:</b>					
(a)	Animal Welfare	2,920.65	3,144.78	3,116.58	2,920.65	3,116.58
(b)	Consumer Products	6,568.01	6,186.62	6,970.15	6,568.01	6,970.15
(c)	Medical Devices	1,367.74	1,592.10	1,048.52	1,367.74	1,048.52
(d)	Protective Devices	4,324.52	4,476.14	3,631.64	4,324.52	3,631.64
(e)	Foods	1,665.60	1,525.38	1,623.88	1,665.60	1,623.88
(f)	Others	136.92	148.60	150.88	136.92	150.88
	<b>Total</b>	<b>16,983.44</b>	<b>17,073.62</b>	<b>16,541.65</b>	<b>16,983.44</b>	<b>16,541.65</b>
	Unallocated	4,630.41	4,695.21	3,996.44	4,630.41	3,996.41
	<b>Total Liabilities</b>	<b>21,613.85</b>	<b>21,768.83</b>	<b>20,538.09</b>	<b>21,613.85</b>	<b>20,538.06</b>

**Notes:**

- Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
- Details of products included in each of the Segments are as below :
  - ❖ Animal Welfare comprise products for Veterinary use.
  - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc.
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - ❖ Foods comprise manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
- Unallocable Expense (Net of Unallocable Income) includes;
  - Profit on sale of leasehold land with building amounting to Rs.1,977.05 lakhs (Net) at Mahindra World City.
  - Write down of inventory amounting to Rs. 586.39 lakhs that were meant for export under USAID program.
- The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai  
Date : May 23, 2025

T T RAGHUNATHAN  
Executive Chairman





## TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

### EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED MARCH 31, 2025

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Year ended	
		(31/03/2025)	(31/12/2024)	(31/03/2024)	(31/03/2025)	(31/03/2024)
		Audited	Unaudited	Audited	Audited	Audited
1.	Total income from Operations	19,035.96	20,474.48	18,105.63	80,149.34	75,279.38
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	2,761.99	2,259.35	2,422.63	9,442.52	8,412.03
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	2,175.60	2,259.35	2,422.63	10,833.18	8,412.03
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	1,614.83	1,673.24	1,827.20	8,165.69	6,284.19
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,052.27	1,575.21	1,627.14	7,825.96	6,166.51
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)				1,04,650.36	98,237.43
8.	Earnings per share (of Rs.10/- each) (for Continuing and Discontinued Operations)					
	(a) Basic (in Rs.)	11.43	11.84	12.93	57.79	44.47
	(b) Diluted (in Rs.)	11.43	11.84	12.93	57.79	44.47

#### Notes:

- The above is an extract of the detailed Statement of Audited Financial Results for the Fourth Quarter and Year ended March 31, 2025, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Fourth Quarter and Year ended March 31, 2025 are available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)), National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- These financial results have been reviewed by the Audit Committee at its meeting held on May 22, 2025 and approved by the Board of Directors of the Company at its meeting held on May 23, 2025 at the Registered Office of the Company, also with the provision of Video Conferencing facility. The Statutory Auditors have audited the above results and have issued an unmodified opinion.
- During the First Quarter of this financial year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
- During the Fourth Quarter of this financial year, the Company has written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond April 01, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- The Board has recommended a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the financial year ended March 31, 2025.
- The figures for the Quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

  
T T RAGHUNATHAN  
Executive Chairman

Place : Chennai  
Date : May 23, 2025

**Independent Auditors' Report**

To

**The Board of Directors of TTK Healthcare Limited**

**Opinion**

1. We have audited the accompanying Financial Results of TTK Healthcare Limited ("the Company"), for the quarter and year ended 31<sup>st</sup> March 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the statement:
  - a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, in this regard;
  - b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter and year ended 31<sup>st</sup> March 2025.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's and Board of Directors' Responsibilities for the Financial Results**

4. This Statement has been prepared on the basis of the audited financial statements for the year ended March 31, 2025.

The Company's Board of Directors are responsible for the preparation and presentation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2025 in accordance with Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with



Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Results**

6. Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.
7. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
  - Conclude on the appropriateness of the Management and the Board of Directors' use of



the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
8. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
  9. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**

10. Attention is drawn to the fact that the figures for the quarter ended 31<sup>st</sup> March 2025 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us. Our opinion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**  
Chartered Accountants  
Firm's Registration No.003990S/S200018

*P. Devi*

Devi P  
Partner  
Membership No 223137  
Place: Chennai  
Date: 23-05-2025  
UDIN: 25223137BMINV9527





---

**TTK Healthcare  
LIMITED**

---

May 23, 2025

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex, Bandra East  
Mumbai 400 051

Scrip Code: 507747

Scrip Code: TTKHLTCARE

Dear Sirs,

**Re : Declaration relating to the Unmodified Opinion by the Statutory Auditors on the Audited Financial Statements for the Fourth Quarter and Year ended March 31, 2025, in accordance with Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015**

---

We hereby declare that the Statutory Auditors of the Company have given their **Unmodified Opinion** on the Audited Financial Statements of the Company for the Fourth Quarter and Year ended March 31, 2025.

Please take the above declaration on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

  
**(T T RAGHUNATHAN)**  
*Executive Chairman*



**TTK Healthcare  
LIMITED**

**ANNEXURE – B**

**Details of Appointment**

<b>Nature of the Person / Firm</b>	<b>M/s Geeyes &amp; Co.</b>
<b>Designation</b>	Cost Auditor
<b>Reason for change viz. appointment, resignation, removal, death or otherwise.</b>	Appointment
<b>Date of appointment / cessation (as applicable) and terms of appointment</b>	May 23, 2025, for a term of one year. (FY 2025-26)
<b>Brief Profile</b>	<p>The firm Geeyes &amp; Co., established in the year 1994, have rich experience in Industry, Consulting and Management Systems Audits, Cost Audits, and Excellence Assessments. They are Cost Auditors for many companies across several industries. Their areas of specialization and interest include Corporate Strategy, Sustainability, Business Excellence, Total Cost Management, Enterprise Risk Management, Corporate Governance, Project Management, Energy &amp; Environmental Management and Supply Chain Management.</p> <p>The Partners of the firm are Mr. S. Srinivasan, Mr. R. Anantharaman, and Mr. Manivannan R. Rajan.</p>
<b>Disclosure of Relationship with Directors</b>	NIL



**TTK Healthcare  
LIMITED**

**ANNEXURE-C**

**HIGHLIGHTS OF THE AUDITED FINANCIAL RESULTS  
FOR THE YEAR ENDED MARCH 31, 2025**

		(Rs. in lakhs)	
		2024-25	2023-24
Revenue from Operations		80,149.34	75,279.38
Other Income		7,125.49	6,260.71
<b>Total Income</b>		<b>87,274.83</b>	81,540.09
Cost of Materials Consumed		36,891.64	33,825.15
Employee Benefits Expense		15,090.96	13,284.00
Other Expenses		24,683.92	24,437.49
<b>Profit before Finance Cost, Depreciation, Exceptional Items and Tax</b>		<b>10,608.31</b>	9,993.45
Finance Cost		332.42	275.55
Depreciation		833.37	1,305.87
<b>Profit before Exceptional Items and Tax</b>		<b>9,442.52</b>	8,412.03
Exceptional Items: Profit on sale of Land / Loss on write-off of Inventories		1390.66	-
<b>Profit before Tax</b>		<b>10,833.18</b>	8,412.03
<b>Less:</b>	Tax Expense		
	Current Tax	2,655.00	2,210.00
	Deferred Tax	12.49	(82.16)
<b>Profit after Tax</b>		<b>8,165.69</b>	6,284.19